 | Up a level |
Freedman, Arnold S., Kuruvilla, John, Assouline, Sarit E., Engert, Andreas, Heo, DaeSeog, Solal-Celigny, Philippe, Corradini, Paolo, Verhoef, Gregor, Fanale, Michelle A., Bendiske, Jennifer, Ewald, Brett, Dey, Jyotirmoy, Baeck, Johan and Younes, Anas (2010). Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592). Blood, 116 (21). S. 129 - 130. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971
Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W., Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny and Mobasher, Mehrdad (2018). High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755